{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T23:54:41Z","timestamp":1775865281657,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20161438"],"award-info":[{"award-number":["BK20161438"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.bioorg.2025.108278","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T12:29:18Z","timestamp":1739968158000},"page":"108278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Design, synthesis and anti-tumor activity of BTK inhibitor Orelabrutinib derivatives"],"prefix":"10.1016","volume":"157","author":[{"given":"Jin","family":"Cai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xintong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6409","key":"10.1016\/j.bioorg.2025.108278_bb0005","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/361226a0","article-title":"The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases","volume":"361","author":"Vetrie","year":"1993","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108278_bb0010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/nchembio.502","article-title":"New Btk inhibitor holds promise","volume":"7","author":"Hendriks","year":"2011","journal-title":"Nat. Chem. Biol."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108278_bb0015","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/leu.2013.358","article-title":"BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity","volume":"28","author":"Cheng","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bioorg.2025.108278_bb0020","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B cell receptor signalling in cancer: preclinical and clinical advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108278_bb0025","first-page":"71","article-title":"Bruton\u2019s tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia","volume":"3","author":"Kil","year":"2013","journal-title":"Am. J. Blood Res."},{"issue":"7277","key":"10.1016\/j.bioorg.2025.108278_bb0030","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108278_bb0035","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cgh.2007.08.019","article-title":"Multiple colorectal neoplasms in X-linked agammaglobulinemia","volume":"6","author":"Brosens","year":"2008","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.bioorg.2025.108278_bb0040","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1080\/1042819031000067576","article-title":"Defective expression of Bruton\u2019s tyrosine kinase in acute lymphoblastic leukemia","volume":"44","author":"Goodman","year":"2003","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.bioorg.2025.108278_bb0045","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S0006-291X(02)02643-8","article-title":"Phosphorylation of Bruton\u2019s tyrosine kinase by c-Abl","volume":"299","author":"B\u00e4ckesj\u00f6","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108278_bb0050","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108278_bb0055","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bioorg.2025.108278_bb0060","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108278_bb0065","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/bjh.12895","article-title":"Breaking good: the inexorable rise of BTK inhibitors in the treatment of chronic lymphocytic leukaemia","volume":"166","author":"Hutchinson","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"18","key":"10.1016\/j.bioorg.2025.108278_bb0070","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1517\/14656566.2015.1109634","article-title":"Ibrutinib: another weapon in our arsenal against lympho-proliferative disorders","volume":"16","author":"Cabras","year":"2015","journal-title":"Expert. Opin. Pharmacother."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108278_bb0075","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cellsig.2012.09.008","article-title":"BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-\u03baB","volume":"25","author":"Rushworth","year":"2013","journal-title":"Cell. Signal."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108278_bb0080","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13045-016-0313-y","article-title":"Second-generation inhibitors of Bruton tyrosine kinase","volume":"9","author":"Wu","year":"2016","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108278_bb0085","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1021\/acs.oprd.1c00443","article-title":"Leveraging high-throughput experimentation to drive pharmaceutical route invention: a four-step commercial synthesis of Branebrutinib (BMS-986195)","volume":"26","author":"Stevens","year":"2022","journal-title":"Org. Process. Res. Dev."},{"issue":"17","key":"10.1016\/j.bioorg.2025.108278_bb0090","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of Zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton\u2019s tyrosine kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108278_bb0095","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40265-021-01482-5","article-title":"Orelabrutinib: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108278_bb0100","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jdcr.2017.06.035","article-title":"Ibrutinib-associated pityriasis rosea-like rash","volume":"4","author":"Bitar","year":"2018","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.bioorg.2025.108278_bb0105","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.omto.2021.03.015","article-title":"Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma","volume":"21","author":"Yu","year":"2021","journal-title":"Mol. Therapy - Oncolytics"},{"issue":"3","key":"10.1016\/j.bioorg.2025.108278_bb0110","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1124\/mol.116.107037","article-title":"Ability of Bruton\u2019s tyrosine kinase inhibitors to sequester Y551 and prevent phosphorylation determines potency for inhibition of fc receptor but not B-cell receptor signaling","volume":"91","author":"Bender","year":"2017","journal-title":"Mol. Pharmacol."},{"issue":"Supplement 1","key":"10.1016\/j.bioorg.2025.108278_bb0115","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1182\/blood-2018-99-109973","article-title":"Potency and selectivity of BTK inhibitors in clinical development for B-cell malignancies","volume":"132","author":"Kaptein","year":"2018","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.bioorg.2025.108278_bb0120","doi-asserted-by":"crossref","first-page":"8552","DOI":"10.1021\/acs.jmedchem.7b01075","article-title":"In silico identification of a novel hinge-binding scaffold for kinase inhibitor discovery","volume":"60","author":"Wang","year":"2017","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2025.108278_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102555","article-title":"BTK kinase activity is dispensable for the survival of diffuse large B-cell lymphoma","volume":"298","author":"Yuan","year":"2022","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108278_bb0130","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12935-019-0754-9","article-title":"ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma","volume":"19","author":"Liu","year":"2019","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bioorg.2025.108278_bb0135","series-title":"B Cell Receptor Signaling","first-page":"67","article-title":"BTK signaling in B cell differentiation and autoimmunity","author":"Corneth","year":"2016"},{"issue":"5","key":"10.1016\/j.bioorg.2025.108278_bb0140","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S1074-7613(00)80417-3","article-title":"Regulation of Btk function by a major autophosphorylation site within the SH3 domain","volume":"4","author":"Park","year":"1996","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.bioorg.2025.108278_bb0145","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1023\/A:1009616228304","article-title":"Role of reactive oxygen species (ROS) in apoptosis induction","volume":"5","author":"Simon","year":"2000","journal-title":"Apoptosis"},{"issue":"9","key":"10.1016\/j.bioorg.2025.108278_bb0150","doi-asserted-by":"crossref","first-page":"5252","DOI":"10.1021\/acs.jmedchem.0c01914","article-title":"Small-molecule inhibitors of reactive oxygen species production","volume":"64","author":"Sassetti","year":"2021","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108278_bb0155","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton\u2019s tyrosine kinase in B cell malignancies","volume":"14","author":"Hendriks","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.bioorg.2025.108278_bb0160","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/ni.2234","article-title":"The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils","volume":"13","author":"Honda","year":"2012","journal-title":"Nat. Immunol."},{"issue":"5381","key":"10.1016\/j.bioorg.2025.108278_bb0165","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.281.5381.1309","article-title":"Mitochondria and apoptosis","volume":"281","author":"Green","year":"1998","journal-title":"Science"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825001580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825001580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T21:35:57Z","timestamp":1763847357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825001580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":33,"alternative-id":["S0045206825001580"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108278","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and anti-tumor activity of BTK inhibitor Orelabrutinib derivatives","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108278","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108278"}}